Division of Otolaryngology-Head and Neck Surgery, Hôpital Maisonneuve-Rosemont, Université de Montréal, 5415 Boul, Assomption, Montreal, QC H1T 2M4, Canada; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Road, Unit 1465, Houston, TX 77030, USA.
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Road, Unit 1465, Houston, TX 77030, USA.
Endocrinol Metab Clin North Am. 2022 Jun;51(2):391-401. doi: 10.1016/j.ecl.2021.11.020. Epub 2022 May 4.
Anaplastic thyroid cancer (ATC) remains one of the most aggressive and deadliest malignancies. Traditionally, treatment consisted of cytotoxic chemotherapy and radiation therapy, with or without surgery, although a large proportion of patients were often directed toward palliative/hospice care. In the past decade, significant advances have been made through the advent of targeted therapies and immunotherapy. For patients with targetable disease and considerable treatment response, surgery and other multidisciplinary adjuvant therapies can now be considered. Overall, the era of untreatable ATC is progressively being replaced by highly personalized multidisciplinary therapies, actively shifting the treatment pendulum of this disease.
间变性甲状腺癌（ATC）仍然是最具侵袭性和致命性的恶性肿瘤之一。传统上，治疗包括细胞毒性化疗和放疗，无论是否手术，尽管很大一部分患者通常被导向姑息/临终关怀。在过去的十年中，通过靶向治疗和免疫疗法的出现取得了重大进展。对于有靶向治疗疾病和相当大的治疗反应的患者，现在可以考虑手术和其他多学科辅助治疗。总的来说，无法治疗的 ATC 时代正在逐渐被高度个性化的多学科治疗所取代，积极改变这种疾病的治疗方向。
